How did Polivy’s trials measure effectiveness?
Polivy (polatuzumab vedotin) trials were designed around clear, objective tumor-response endpoints rather than only symptom improvement. The key approach was to test whether adding Polivy to a backbone of chemotherapy improves the rate of clinically meaningful tumor shrinkage compared with the control regimen.
In Polivy’s pivotal setting for diffuse large B-cell lymphoma (DLBCL) that is relapsed or refractory, the effectiveness goal centered on tumor response assessed using standard oncology criteria, with results reported as the proportion of patients whose tumors met predefined response thresholds (for example, complete or partial response) and how long those responses lasted [1][2].
What trial design did the pivotal studies use (randomization, control arms)?
The pivotal effectiveness evidence came from randomized, controlled studies in relapsed/refractory DLBCL. Patients were assigned to receive Polivy plus a chemotherapy regimen versus a control arm that received the same or similar chemotherapy backbone without Polivy (and in some designs, with differences in the second component as specified by the study protocol) [1][2].
This randomized, comparative structure is what lets investigators attribute differences in response rates and durability to the addition of Polivy rather than to differences between patient groups.
What endpoints had to be met to show Polivy worked?
Effectiveness was demonstrated using endpoints that can be measured consistently across sites:
- Tumor response rate (objective response based on imaging assessments) [1][2]
- Response durability, reflected by time-to-event measures such as how long responses last [1][2]
These endpoints are commonly used in oncology trials because they translate directly into measurable changes in tumor burden.
How did Polivy’s trials handle timing and follow-up?
Because durability matters for treatments intended to improve outcomes over time, designs included sufficient follow-up to observe whether responses were maintained and whether patients proceeded to subsequent therapies. The effectiveness analyses used ongoing assessment schedules consistent with standard imaging-based response evaluation in lymphoma studies [1][2].
What populations were included to test effectiveness?
The studies focused on patients with relapsed or refractory DLBCL populations matching the intended use described in regulatory materials, including treatment histories that made them appropriate candidates for the added benefit Polivy was designed to provide [1][2].
What results from these designs were used to support approval?
Regulatory documentation ties effectiveness conclusions to the trial endpoints described above and reports improvements in objective response and response duration in the Polivy-containing arms compared with control arms [1][2].
---
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761157s012lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761055s022lbl.pdf